Back to top
more

Vaxxinity (VAXX)

(Delayed Data from OTC)

$0.00 USD

0.00
6,688

0.00 (100.00%)

Updated Nov 8, 2024 01:55 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Balance Sheet

Research for VAXX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Vaxxinity, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 31 88 145 31 0
Receivables 0 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 3 6 9 5 1
Total Current Assets 33 94 154 36 1
Net Property & Equipment 11 13 12 12 0
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 2 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 0 0 0 0 0
Total Assets 44 106 167 50 2
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 2 2 0 28 13
Accounts Payable 2 5 3 1 1
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 3 11 5 1 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 11 13 19 8 5
Total Current Liabilities 18 31 27 37 20
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 1
Long-Term Debt 13 13 10 11 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 27 2
Minority Interest (Liabilities) 0 0 0 62 27
Total Liabilities 31 44 38 138 50
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 375 367 358 5 4
Retained Earnings -362 -305 -229 -92 -52
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 13 62 129 -87 -49
Total Liabilities & Shareholder's Equity 44 106 167 50 2
Total Common Equity 13 62 129 -87 -49
Shares Outstanding 126.70 126.00 125.30 NA NA
Book Value Per Share 0.11 0.49 1.03 0.00 0.00

Fiscal Year End for Vaxxinity, Inc falls in the month of December.

All items in Millions except Per Share data.

9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Assets          
Cash & Equivalents -99,999 -99,999 -99,999 31 43
Receivables NA NA NA 0 0
Notes Receivable NA NA NA 0 0
Inventories NA NA NA 0 0
Other Current Assets NA NA NA 3 4
Total Current Assets NA NA NA 33 46
Net Property & Equipment NA NA NA 11 11
Investments & Advances NA NA NA 0 0
Other Non-Current Assets NA NA NA 0 0
Deferred Charges NA NA NA 0 0
Intangibles NA NA NA 0 0
Deposits & Other Assets NA NA NA 0 0
Total Assets NA NA NA 44 57
Liabilities & Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Notes Payable NA NA NA 2 1
Accounts Payable NA NA NA 2 3
Current Portion Long-Term Debt NA NA NA 0 0
Current Portion Capital Leases NA NA NA 0 0
Accrued Expenses NA NA NA 3 5
Income Taxes Payable NA NA NA 0 0
Other Current Liabilities NA NA NA 11 13
Total Current Liabilities NA NA NA 18 22
Mortgages NA NA NA 0 0
Deferred Taxes/Income NA NA NA 0 0
Convertible Debt NA NA NA 0 0
Long-Term Debt NA NA NA 13 12
Non-Current Capital Leases NA NA NA 0 0
Other Non-Current Liabilities NA NA 0 0
Minority Interest (Liabilities) NA NA NA 0 0
Total Liabilities NA NA NA 31 34
Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Preferred Stock NA NA NA 0 0
Common Stock (Par) NA NA NA 0 0
Capital Surplus NA NA NA 375 374
Retained Earnings NA NA NA -362 -350
Other Equity NA NA NA 0 0
Treasury Stock NA NA NA 0 0
Total Shareholder's Equity NA NA NA 13 24
Total Liabilities & Shareholder's Equity NA NA NA 44 57
Total Common Equity 0 0 0 13 24
Shares Outstanding 126.70 126.70 126.70 126.70 126.70
Book Value Per Share 0.00 0.00 0.00 0.11 0.19